A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase IV
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Umeclidinium/vilanterol (Primary) ; Olodaterol/tiotropium bromide; Salbutamol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 May 2017 This trial has been completed in Germany.
- 04 May 2017 This trial has been completed in Spain (End date: 2017-04-12) as per European Clinical Trials Database record.